Literature DB >> 33181268

Vasopressin and copeptin release during sepsis and septic shock.

Dayane Aparecida Gomes1, Raphaelle Lima de Almeida Beltrão2, Flavio Monteiro de Oliveira Junior2, José Carlos da Silva Junior2, Eduarda Patrícia Carneiro de Arruda2, Eduardo Carvalho Lira2, Maria José Alves da Rocha3.   

Abstract

Sepsis is defined as a potentially fatal organ dysfunction caused by a dysregulated host response to infection. Despite tremendous progress in the medical sciences, sepsis remains one of the leading causes of morbidity and mortality worldwide. The host response to sepsis and septic shock involves changes in the immune, autonomic, and neuroendocrine systems. Regarding neuroendocrine changes, studies show an increase in plasma vasopressin (AVP) concentrations followed by a decline, which may be correlated with septic shock. AVP is a peptide hormone derived from a larger precursor (preprohormone), along with two peptides, neurophysin II and copeptin. AVP is synthesized in the hypothalamus, stored and released from the neurohypophysis into the bloodstream by a wide range of stimuli. The measurement of AVP has limitations due to its plasma instability and short half-life. Copeptin is a more stable peptide than AVP, and its immunoassay is feasible. The blood concentrations of copeptin mirror those of AVP in many physiological states; paradoxically, during sepsis-related organ dysfunction, an uncoupling between copeptin and AVP blood levels appears to happen. In this review, we focus on clinical and experimental studies that analyzed AVP and copeptin blood concentrations over time in sepsis. The findings suggest that AVP and copeptin behave similarly in the early stages of sepsis; however, we did not find a proportional decrease in copeptin concentrations as seen with AVP during septic shock. Copeptin levels were higher in nonsurvivors than in survivors, suggesting that copeptin may work as a marker of severity or sepsis-related organ dysfunction.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Hormone secretion; Hypothalamus; Infection; Neurohypophysis; Organ dysfunction

Mesh:

Substances:

Year:  2020        PMID: 33181268     DOI: 10.1016/j.peptides.2020.170437

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

Review 1.  The role of copeptin in kidney disease.

Authors:  Pedro Iglesias; Ramona A Silvestre; María José Fernández-Reyes; Juan J Díez
Journal:  Endocrine       Date:  2022-10-15       Impact factor: 3.925

2.  Approach to the Patient: "Utility of the Copeptin Assay".

Authors:  Mirjam Christ-Crain; Julie Refardt; Bettina Winzeler
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

3.  The diagnostic and prognostic value of copeptin in patients with acute ischemic stroke and transient ischemic attack: A systematic review and meta-analysis.

Authors:  Natasza Blek; Piotr Szwed; Paulina Putowska; Adrianna Nowicka; Wiktoria L Drela; Aleksandra Gasecka; Jerzy R Ladny; Yaroslaw Merza; Milosz J Jaguszewski; Lukasz Szarpak
Journal:  Cardiol J       Date:  2022-05-27       Impact factor: 3.487

4.  Risk assessment of sepsis through measurement of proAVP (copeptin): a secondary analysis of the TRIAGE study.

Authors:  Milena Kloter; Claudia Gregoriano; Ellen Haag; Alexander Kutz; Beat Mueller; Philipp Schuetz
Journal:  Endocr Connect       Date:  2021-08-24       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.